Drug-Ad Fight Looms in Congress

Advertising trade groups are bracing for a fight as lawmakers threaten to dampen what has become a $2 billion-plus market in the five years since federal law opened up direct-to-consumer advertising to drug companies.

One lawmaker earlier this month introduced a bill to curb pharmaceutical ad vertising, and another has vowed to revive efforts to introduce similar legislation that was defeated last year.

When this year began, lobby groups were breathing a little easier about the prospects for anti-drug-ad legislation, hoping that new Senate majority leader Bill Frist, R-Tenn.,

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in